Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms Caused by Lenalidomide: Case Report and Review of the Literature
DOI:
https://doi.org/10.2340/00015555-3835Abstract
Abstract is missing (Short communication)
Downloads
References
Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int 2019; 68: 301-308.
DOI: https://doi.org/10.1016/j.alit.2019.03.006
Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011; 36: 6-11.
DOI: https://doi.org/10.1111/j.1365-2230.2010.03967.x
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071-1080.
DOI: https://doi.org/10.1111/bjd.12501
Foti C, Antelmi A, Mazzocca A, Saverio Vella F, Romita P, Pugliese S, et al. Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide. Eur J Dermatol 2012; 22: 799-800.
DOI: https://doi.org/10.1684/ejd.2012.1853
Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract 2014; 20: 302-304.
DOI: https://doi.org/10.1177/1078155213502569
Vlachopanos G, Kokkona A, Zerva A, Stavroulaki E, Zacharogiannis C, Agrafiotis A. Atypical DRESS syndrome induced by lenalidomide in chronic hemodialysis. J Clin Exp Pathol 2016; 6: 277.
DOI: https://doi.org/10.4172/2161-0681.1000277
Shanbhag A, Pritchard ER, Chatterjee K, Hammond DA. Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide. Hosp Pharm 2017; 52: 408-411.
DOI: https://doi.org/10.1177/0018578717717394
Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol 2019; 80: 670-678.e2.
DOI: https://doi.org/10.1016/j.jaad.2018.08.052
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, Mcconkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301-305.
DOI: https://doi.org/10.1126/science.1244851
Lu G, Middleton RE, Sun H, Naniong MV, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 2014; 343: 305-309.
DOI: https://doi.org/10.1126/science.1244917
Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Shin-ichi Osada, Takahiko Sato
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
